While the pharmaceutical industry has been mostly untouched in the Trump administration’s first 22 months, according to an MM&M report, a new Democratic House and shifting political landscape could mean change is on the horizon.
Though little action has been taken against the industry, per the report, it spent some $267 million on lobbying between 2017-18, and donated $12 million to congressional candidates.
“What I’ve seen has been almost nothing of significance on the legislative side and only a little on the administrative side,” Polsinelli Senior Policy Adviser Julius Hobson tells MM&M. “The only folks who have seen trouble are the pharmacy benefit [managers]. They’re in the middle and everybody’s shooting at them.”
The political climate is changing toward the pharmaceutical industry, too, including joint, bipartisan efforts by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Oregon). Grassley and Wyden recently announced bipartisan legislation that would tighten regulations around Medicaid rebates to prevent drugmakers from overcharging taxpayers.